Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 46, 2010, Pages 19997-20002

  Su, Feng ^a   Kozak, Kathy R ^a,d   Imaizumi, Satoshi ^a   Gao, Feng ^a   Amneus, Malaika W ^a   Grijalva, Victor ^a   Ng, Carey ^a,e   Wagner, Alan ^a   Hough, Greg ^a   Farias Eisner, Gina ^a,f   Anantharamaiah, G M ^c   Van Lenten, Brian J ^a   Navab, Mohamad ^a   Fogelman, Alan M ^a   Reddy, Srinivasa T ^a,b   Farias Eisner, Robin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Alabama at Birmingham   (United States)

^d GENENTECH INC   (United States)

^e Mesa Verde Venture Partners   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; CISPLATIN; D 4F PEPTIDE; L 4F PEPTIDE; L 5F PEPTIDE; LYSOPHOSPHATIDIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CARCINOMA CELL; CELL PROLIFERATION; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

MUS;

EID: 78650571356     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009010107     Document Type: Article

References (56)

1. Edwards BK, et al. (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-573.
2. Nossov V, et al. (2008) The early detection of ovarian cancer: From traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199:215-223.
3. Kozak KR, et al. (2003) Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 100:12343-12348.
4. Kozak KR, et al. (2005) Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5:4589-4596.
5. Su F, et al. (2007) Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2:369-375.
6. Nosov V, et al. (2009) Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 200:639.e1-639.e5.
7. Tardif JC, Heinonen T, Noble S (2009) High-density lipoprotein/ apolipoprotein A-I infusion therapy. Curr Atheroscler Rep 11(1):58-63.
8. Navab M, et al. (2005) Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res 97:524-532.
9. Reddy ST, et al. (2006) Oral amphipathic peptides as therapeutic agents. Expert Opin Investig Drugs 15(1):13-21.
10. Van Lenten BJ, et al. (2008) Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. Curr Opin Investig Drugs 9:1157-1162.
11. Navab M, et al. (2009) A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res 50:1538-1547.
12. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M (2009) In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 76:437-444.
13. Van Lenten BJ, et al. (2009) Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep 11(1):52-57.
14. Xu Y, Fang XJ, Casey G, Mills GB (1995) Lysophospholipids activate ovarian and breast cancer cells. Biochem J 309:933-940.
15. Xiao YJ, et al. (2001) Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: Comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290:302-313.
16. Boucharaba A, et al. (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 103:9643-9648.
17. Kitayama J, et al. (2004) Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 6:R640-R646.
18. Baker DL, et al. (2002) Plasma lysophosphatidic acid concentration and ovarian ancer. J MA 287:3081-3082.
19. Sutphen R, et al. (2004) Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13:1185-1191.
20. Li H, et al. (2009) Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther 8:1692-1701.
21. Roby KF, et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21:585-591.
22. Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J (2009) ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 8:64-74.
23. Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC (2003) Src tyrosine kinase promotessurvival and resistanceto chemotherapeuticsin a mouseovarian cancer cell line. Biochem Biophys Res Commun 309:377-383.
24. Navab M, et al. (2002) Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105:290-292.
25. Navab M, et al. (2004) Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109:3215-3220.
26. Van Lenten BJ, et al. (2008) Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49:2302-2311.
27. Nicotera TM, Privalle C, Wang TC, Oshimura M, Barrett JC (1994) Differential proliferative responses of Syrian hamster embryo fibroblasts to paraquat-generated superoxide radicals depending on tumor suppressor gene function. Cancer Res 54:3884-3888.
28. Loo G (2003) Redox-sensitive mechanisms of phytochemical-mediated inhibition of cancer cell proliferation (review). J Nutr Biochem 14:64-73.
29. Hu Y, et al. (2005) Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: Rolein cell proliferation and response to oxidative stress. J Biol Chem 280:39485-39492.
30. Bochkov VN, et al. (2010) Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 12:1009-1059.
31. Wang L, et al. (2009) Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 50:204-213.
32. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosisstatin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109:573-579.
33. Platz EA, et al. (2006)Statin drugsand risk of advanced prostate cancer. J Natl Cancer Inst 98:1819-1825.
34. Elmore RG, Ioffe YI, Scoles DR, Karlan BY, Li AJ (2008) Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol 111:102-105.
35. Li AJ, Elmore RG, Chen IY, Karlan BY (2010)Serumlow-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. Gynecol Oncol 116:78-81.
36. Camuzcuoglu H, et al. (2009) Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol 112:481-485.
37. Ehmann M, et al. (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34:205-214.
38. Takaishi S, Wang TC (2007) Gene expression profiling in a mouse model of Helicobacter-induced gastric cancer. Cancer Sci 98:284-293.
39. Halton JM, Nazir DJ, McQueen MJ, Barr RD (1998) Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer 83:379-384.
40. Scribano D, et al. (1996) Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Haematologica 81:343-345.
41. Navab M, et al. (2010) Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 30:164-168.
42. Van Lenten BJ, et al. (2007) Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 48:2344-2353.
43. Mahdavi H, Kim JB, Safarpour S, Tien DA, Navab M (2009) Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol 20:157-158.
44. Van Lenten BJ, et al. (2002) Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106:1127-1132.
45. Watanabe J, et al. (2009) Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 284:18292-18301.
46. Ou J, et al. (2005) Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/ apolipoprotein A-I doubleknockout mice on Western diet. Circ Res 97:1190-1197.
47. Peterson SJ, et al. (2008) L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivityin obese mice. J Lipid Res 49:1658-1669.
48. Peterson SJ, et al. (2009) The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 50:1293-1304.
49. Kaysen GA (2009) Potential restoration of HDL function with apolipoprotein A-I mimetic peptide in end-stage renal disease. Kidney Int 76:359-361.
50. Zhang Z, et al. (2009) Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol 297:H866-H873.
51. Handattu SP, et al. (2009) Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol Dis 34:525-534.
52. Wang J, Zhou JY, Zhang L, Wu GS (2009) Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 8:3191-3198.
53. Reddy ST, et al. (2002) Identification of genes induced by oxidized phospholipids in human aortic endothelial cells. Vascul Pharmacol 38:211-218.
54. Reddy ST, et al. (2004) Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models. Arterioscler Thromb Vasc Biol 24:1676-1681.
55. Cannistra SA(2004) Cancer of the ovary. N Engl J Med 351:2519-2529.
56. Murph M, et al. (2007) Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: Potential biomarkers for cancer diagnosis. Methods Enzymol 433:1-25.